On Dec. 23, 2019, the USPTO issued a rare precedential decision in Ex parte Linden, relating to AI patent application eligibility. The USPTO has also recently requested comments from the public relating to patentability issues affecting AI inventions, signaling that more policy or examination guideline changes are being considered. At the same time, AI is rapidly reshaping the drug discovery process, altering the delivery of healthcare to patients, automating diagnoses, and accelerating the trend of personalized medicine with the creation of digital biomarkers and wearable technology to optimize therapeutic outcomes. We invite you to join us for a seminar on Wed. Feb. 5, 2019 at 4-5 PM, providing an update concerning these new developments in U.S. patent practice. Registration will begin at 3:45 PM.
Please RSVP to Tamaki Honda at email@example.com by Monday, February 3rd.
CLE credits will be applied for in all applicable states. This activity is pending approval by the State Bar of California in the amount up to 1.0 general credits.